0001213900-24-052869.txt : 20240614 0001213900-24-052869.hdr.sgml : 20240614 20240614160013 ACCESSION NUMBER: 0001213900-24-052869 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240614 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SciSparc Ltd. CENTRAL INDEX KEY: 0001611746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38041 FILM NUMBER: 241044578 BUSINESS ADDRESS: STREET 1: 20 RAUL WALLENBERG STREET, TOWER A CITY: TEL AVIV STATE: L3 ZIP: 6971916 BUSINESS PHONE: 972-3-6103100 MAIL ADDRESS: STREET 1: 20 RAUL WALLENBERG STREET, TOWER A CITY: TEL AVIV STATE: L3 ZIP: 6971916 FORMER COMPANY: FORMER CONFORMED NAME: SciSparc Ltd./ADR DATE OF NAME CHANGE: 20210129 FORMER COMPANY: FORMER CONFORMED NAME: Therapix Biosciences Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0207903-6k_scisparc.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2024 (Report No. 2)

Commission file number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On June 9, 2024, SciSparc Ltd. (the “Company”) entered into an amendment (the “Amendment”) to the bridge loan agreement previously announced by the Company on January 19, 2024 (the “Loan Agreement”) with AutoMax Motors Ltd. (“AutoMax”). Pursuant to the Amendment, the Company made available to AutoMax an additional loan in the amount of $1.0 million under terms similar to the Loan Agreement.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670, File No. 333-255408, and File No. 333-275305) and on Form S-8 (File No. 333-278437, and File No. 333-225773) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SciSparc Ltd.

Date: June 14, 2024	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer